Who makes Heparin 50U/ml?

Heparin 50U/ml is developed by University of Florence.

What development phase is Heparin 50U/ml in?

Heparin 50U/ml is FDA-approved (marketed).

What are the side effects of Heparin 50U/ml?

Common side effects include Bleeding, Heparin-induced thrombocytopenia (HIT), Thrombosis, Osteoporosis (with prolonged use).

Last reviewed 2026-04-22 · How we verify

Heparin 50U/ml

University of Florence · FDA-approved active Small molecule

Heparin is an anticoagulant that inhibits blood clotting by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.

Heparin is an anticoagulant that inhibits blood clotting by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors. Used for Thromboembolism prophylaxis and treatment, Acute coronary syndrome, Deep vein thrombosis prevention and treatment.

At a glance

Generic name	Heparin 50U/ml
Also known as	Heparin solution 50 U/ml, Epsodilave
Sponsor	University of Florence
Drug class	Anticoagulant (unfractionated heparin)
Target	Antithrombin III (indirect mechanism); Thrombin and Factor Xa (downstream targets)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Heparin binds to and potentiates antithrombin III, a natural inhibitor of coagulation proteases. This complex rapidly inactivates thrombin (Factor IIa) and Factor Xa, preventing the formation of fibrin clots and the propagation of thrombosis. Heparin is a naturally occurring glycosaminoglycan extracted from animal tissues and acts as an indirect anticoagulant.

Approved indications

Thromboembolism prophylaxis and treatment
Acute coronary syndrome
Deep vein thrombosis prevention and treatment
Pulmonary embolism treatment

Common side effects

Bleeding
Heparin-induced thrombocytopenia (HIT)
Thrombosis
Osteoporosis (with prolonged use)

Key clinical trials

Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Heparin 50U/ml CI brief — competitive landscape report
Heparin 50U/ml updates RSS · CI watch RSS
University of Florence portfolio CI